Axitinib AXIS



Axitinib AXIS **Axitinib AXIS** PRELIMINARY SCORE **FINAL SCORE** CURATIVE **CURATIVE** Overall Survival / Disease-Free Survival / Pathological Complete Response **NON-CURATIVE NON-CURATIVE** Overall Survival **ADJUSTMENTS** Quality of life Progression-Free Survival No QoL benefit Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Serious and disabling adverse effects Overall Response Rate / Duration of Response Less serious adverse events observed Overall Survival / Disease-Free Survival / Pathological Complete Response Other adjustments INFORMATION Tumour type: Genitourinary Cancers Therapeutic Indication: Treatment of adult patients with advanced RCC after failure of prior treatment with sunitinib or cytokine Only improved PFS mature data shows no Experimental Arm: Axitinib Control Arm: Sorafenib OS advantage and no improved QoL



© 2023 | European Society for Medical Oncology | ESMO - MCBS 1.1 | All rights reserved worldwide.